{"document_type": "article", "byline": {"person": [{"role": "reported", "firstname": "Clyde", "organization": "", "rank": 1, "lastname": "HABERMAN"}], "original": "By CLYDE HABERMAN"}, "news_desk": "National", "slideshow_credits": null, "abstract": null, "multimedia": [{"type": "image", "url": "images/2016/12/12/us/12RETRO/12RETRO-thumbWide.jpg", "legacy": {"wide": "images/2016/12/12/us/12RETRO/12RETRO-thumbWide.jpg", "wideheight": "126", "widewidth": "190"}, "width": 190, "subtype": "wide", "height": 126}, {"type": "image", "url": "images/2016/12/12/us/12RETRO/12RETRO-articleLarge.jpg", "legacy": {"xlarge": "images/2016/12/12/us/12RETRO/12RETRO-articleLarge.jpg", "xlargewidth": "600", "xlargeheight": "400"}, "width": 600, "subtype": "xlarge", "height": 400}, {"type": "image", "url": "images/2016/12/12/us/12RETRO/12RETRO-thumbStandard.jpg", "legacy": {"thumbnail": "images/2016/12/12/us/12RETRO/12RETRO-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "width": 75, "subtype": "thumbnail", "height": 75}], "headline": {"content_kicker": "Retro Report", "main": "Lives and Profits in the Balance: The High Stakes of Medical Patents"}, "print_page": null, "keywords": [{"value": "Drugs (Pharmaceuticals)", "is_major": "N", "rank": "1", "name": "subject"}, {"value": "Inventions and Patents", "is_major": "N", "rank": "2", "name": "subject"}, {"value": "Prices (Fares, Fees and Rates)", "is_major": "N", "rank": "3", "name": "subject"}, {"value": "Gleevec (Drug)", "is_major": "N", "rank": "4", "name": "subject"}, {"value": "Novartis AG", "is_major": "N", "rank": "6", "name": "organizations"}, {"value": "Advertising and Marketing", "is_major": "N", "rank": "7", "name": "subject"}], "snippet": "Tensions inherent to drug pricing pit affordability against the need to recoup investment in research, raising questions about how much of the cost patients should have to bear....", "source": "The New York Times", "lead_paragraph": "Tensions inherent to drug pricing pit affordability against the need to recoup investment in research, raising questions about how much of the cost patients should have to bear.", "word_count": "1373", "pub_date": "2016-12-12T00:09:21+0000", "subsection_name": null, "blog": [], "type_of_material": "News", "section_name": "U.S.", "web_url": "http://www.nytimes.com/2016/12/11/us/retro-report-medical-patents-profits.html", "_id": "584deab895d0e0392607566e"}